Related Experiment Videos
[Lipodystrophy in HIV infected children]
Jolanta Popielska1, Magdalena Marczyńska
1Klinika Chorób Zakaźnych Wieku Dzieciecego, Akademia Medyczna, ul. Wolska 37, 01-201 Warszawa. jolantapopielska@wp.pl
Medycyna Wieku Rozwojowego
|June 14, 2005
Summary
Lipodystrophy is increasingly recognized in HIV-infected children on Highly Active Antiretroviral Therapy (HAART). This study found lipodystrophy in 9/40 children, with frequent metabolic abnormalities, highlighting treatment risks.
Area of Science:
- Pediatric Endocrinology
- Infectious Diseases
- Metabolic Disorders
Context:
- Lipodystrophies are rare genetic or acquired conditions characterized by abnormal fat distribution and metabolic disturbances.
- Increased recognition of lipodystrophy in HIV-infected individuals undergoing antiretroviral therapy.
- Potential link between antiretroviral drugs and the development of lipodystrophy and associated metabolic complications.
Purpose:
- To determine the prevalence of lipodystrophy in children infected with HIV who are receiving Highly Active Antiretroviral Therapy (HAART).
- To assess the clinical and metabolic manifestations associated with lipodystrophy in this pediatric population.
- To identify potential risk factors and contributing factors to lipodystrophy in HIV-infected children on HAART.
Summary:
- A study of 40 HIV-infected children (ages 3-16) on HAART for a median of 4 years found lipodystrophy in 9 (22.5%).
- All children with lipodystrophy exhibited metabolic abnormalities and clinical signs, often linked to specific antiretroviral drugs (Zerit, Videx, Kaletra).
- Metabolic abnormalities, including abnormal serum lipids, were also frequent in children without overt lipodystrophy, suggesting subclinical effects.
Impact:
- Highlights the significant prevalence of lipodystrophy and associated metabolic derangements in HIV-infected children on HAART.
- Suggests that the duration of HAART and specific drug regimens (e.g., Zerit, Videx, Kaletra) may increase the risk of lipodystrophy.
- Emphasizes the need to monitor for metabolic abnormalities in all HAART-treated children, even those without clinical lipodystrophy, to guide therapeutic choices and modifications.